International Application Published under the Patent Cooperation Treaty (PCT)

Title: 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE DERIVATIVES AS IMMUNOMODULATORS

Abstract: The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also refers to derivatives of the therapeutic agents.

The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotenti - ation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.
1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE DERIVATIVES AS IMMUNOMODULATORS

This application claims the benefit of Indian provisional application number 4012/CHE/2013, filed on September 06, 2013; which hereby incorporated by reference.

TECHNICAL FIELD

The present invention relates to 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds therapeutically useful as immune modulators. The invention also relates to pharmaceutical compositions comprising the said 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents.

BACKGROUND OF THE INVENTION

Programmed cell death-1 (PD-1) is a member of the CD28 superfamily that delivers negative signals upon interaction with its two ligands, PD-L1 or PD-L2. PD-1 and its ligands are broadly expressed and exert a wider range of immunoregulatory roles in T cells activation and tolerance compared with other CD28 members. PD-1 and its ligands are involved in attenuating infectious immunity and tumor immunity, and facilitating chronic infection and tumor progression. The biological significance of PD-1 and its ligand suggests the therapeutic potential of manipulation of PD-1 pathway against various human diseases (Ariel Pedoeem et al., Curr Top Microbiol Immunol. (2011); 350:17-37).

T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response (Li Shi, et al., Journal of Hematology & Oncology 2013, 6:74).

Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell down regulation and promote immune responses against cancer. Several PD-1 pathway inhibitors have shown robust activity in various phases of clinical trials (RD Harvey, Clinical Pharmacology & Therapeutics (2014); 96 2, 214-223).

Programmed death-1 (PD-1) is a co-receptor that is expressed predominantly by T cells. The binding of PD-1 to its ligands, PD-L1 or PD-L2, is vital for the physiological regulation of the immune system. A major functional role of the PD-1 signaling pathway is the inhibition of self-reactive T cells, which serve to protect against
autoimmune diseases. Elimination of the PD-1 pathway can therefore result in the breakdown of immune tolerance that can ultimately lead to the development of pathogenic autoimmunity. Conversely, tumor cells can at times co-opt the PD-1 pathway to escape from immunosurveillance mechanisms. Therefore, blockade of the PD-1 pathway has become an attractive target in cancer therapy. Current approaches include six agents that are either PD-1 and PD-L1 targeted neutralizing antibodies or fusion proteins. More than forty clinical trials are underway to better define the role of PD-1 blockade in variety of tumor types. (Hyun-Tak Jin et al., Clinical Immunology (Amsterdam, Netherlands) (2014), 153(1), 145-152).


Further, International applications, WO2011161699, WO2012/168944, WO2013144704 and WO2013132317 report peptides or peptidomimetic compounds which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway.

Still there is a need for more potent, better and/or selective immune modulators of PD-1 pathway. The present invention provides 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signalling pathway.

SUMMARY OF INVENTION

In accordance with the present invention, 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds or a pharmaceutically acceptable salt or a stereoisomer thereof, provided which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signalling pathway.

In one aspect, the present invention provides a 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds of formula (I):
wherein,

- **R₁** is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
- **X** is S or O;
- **R₂** is hydrogen or -CO-Aaa;
- **Aaa** is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified;
- **R₃** is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
  - is an optional bond;
- **R₄** and **R₅** independently are hydrogen or absent;
- or a pharmaceutically acceptable salt or a stereoisomer thereof.

In a further aspect of the present invention, it relates to the pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

In yet another aspect of the present invention, it provides use of 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof, which are capable of suppressing and/or inhibiting the programmed cell death 1 (PD1) signaling pathway.

**DETAILED DESCRIPTION OF THE INVENTION**

The present invention provides 1,3,4-oxadiazole and 1,3,4-thiadiazole compounds as therapeutic agents useful for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.

Each embodiment is provided by way of explanation of the invention, and not by way of limitation of the invention. In fact, it will be apparent to those skilled in the art that various modification and variations can be made in the present invention without departing from the scope or spirit of the invention. For instance, features illustrated or described as part of one embodiment can be used on another embodiment to yield a still further embodiment. Thus it is intended that the present invention cover such
modifications and variations as come within the scope of the appended claims and their equivalents. Other objects, features, and aspects of the present invention are disclosed in, or are obvious from, the following detailed description. It is to be understood by one of ordinary skill in the art that the present discussion is a description of exemplary embodiments only, and is not to be construed as limiting the broader aspects of the present invention.

In one embodiment, the present invention relates to compounds of formula (I)

\[
\begin{array}{c}
H_2N - R_1 - X - R_3 \\
\mid \quad \mid \\
N - N - R_2 \\
\mid \quad \mid \\
R_4 \quad R_5
\end{array}
\]

wherein,

- \( R_1 \) is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
- \( X \) is S or O;
- \( R_2 \) is hydrogen or -CO-Aaa;
- Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a \( C- \) terminus thereof is a free terminus, is amidated or is esterified;
- \( R_3 \) is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
- \(-\) is an optional bond;
- \( R_4 \) and \( R_5 \) independently are hydrogen or absent;
- or a pharmaceutically acceptable salt or a stereoisomer thereof.

In yet another embodiment, the present invention provides compounds of formula (IA)

\[
\begin{array}{c}
H_2N - R_1 - X - R_3 \\
\mid \quad \mid \\
N - N - R_2 \\
\mid \quad \mid \\
R_4 \quad R_5
\end{array}
\]

or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,

- \( R_1 \) is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
- \( X \) is S or O;
- \( R_2 \) is hydrogen or -CO-Aaa;
- \( R_3 \) is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified.

In yet another further embodiment, the present invention provides compounds of formula (IB)

\[
\begin{align*}
& \text{H}_2\text{N} \begin{array}{c} \text{R}_1 \end{array} \begin{array}{c} \text{S} \end{array} \begin{array}{c} \text{N} \end{array} \begin{array}{c} \text{N} \end{array} \begin{array}{c} \text{Aaa} \end{array} \\
\end{align*}
\]

or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
\( R_1 \) is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
\( R_3 \) is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified.

In yet another further embodiment, the present invention provides compounds of formula (IC)

\[
\begin{align*}
& \text{H}_2\text{N} \begin{array}{c} \text{R}_1 \end{array} \begin{array}{c} \text{O} \end{array} \begin{array}{c} \text{N} \end{array} \begin{array}{c} \text{N} \end{array} \begin{array}{c} \text{Aaa} \end{array} \\
\end{align*}
\]

or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
\( R_1 \) is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
\( R_3 \) is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified.

In yet another further embodiment, the present invention provides compounds of formula (I), wherein,
\( R_1 \) is side chain of Ser or Thr;
\( R_2 \) is -CO-Aaa;
Aaa is an amino acid residue Ser or Thr; wherein the C-terminus is free;
\( R_3 \) is side chain of Asn, Gin, Glu or Asp.

The embodiment below are illustrative of the present invention and are not intended to limit the claims to the specific embodiments exemplified.
According to one embodiment, specifically provided are compounds of the formula (I) and (IA), in which X is O.

According to another embodiment, specifically provided are compounds of the formula (I) and (IA) in which X is S.

According to yet another embodiment, specifically provided are compounds of the formula (I) and (IA) in which $R_2$ is hydrogen.

According to yet another embodiment, specifically provided are compounds of the formula (I) in which $R_4$ and $R_5$ are hydrogen.

According to yet another embodiment, specifically provided are compounds of the formula (I) in which $R_4$ and $R_5$ are absent.

According to yet another embodiment, specifically provided are compounds of the formula (I) in which $R_2$ is -CO-Ser.

According to yet another embodiment, specifically provided are compounds of the formula (I) in which $R_2$ is -CO-Thr.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA), (IB) and (IC) in which $R_i$ is side chain of Ser.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA), (IB) and (IC) in which $R_1$ is side chain of Thr.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IC) in which $R_1$ is side chain of Phe, Ala or Asn.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IC) in which $R_3$ is side chain of Asn.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IB) in which $R_1$ is side chain of Ser.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IC) in which $R_3$ is side chain of Gin.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IC) in which $R_3$ is side chain of Glu.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IC) in which $R_3$ is side chain of Ala or Asp.

According to yet another embodiment, specifically provided are compounds of the formula (IB) and (IC) in which Aaa is Ser.
According to yet another embodiment, specifically provided are compounds of the formula (IC) in which Aaa is Thr.

According to yet another embodiment, specifically provided are compounds of the formula (I), (IA) and (IB) in which one, more or all amino acid/s is/are D amino acid/s.

In an embodiment, specific compounds of formula (I) without any limitation are enumerated in Table (1):

<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Structure</th>
</tr>
</thead>
</table>
| 1.           | ![Structure 1](image1)
| 2.           | ![Structure 2](image2)
| 3.           | ![Structure 3](image3)
| 4.           | ![Structure 4](image4)
| 5.           | ![Structure 5](image5)
<p>| 6.           | <img src="image6" alt="Structure 6" /> |</p>
<table>
<thead>
<tr>
<th></th>
<th>Chemical Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.</td>
<td><img src="image" alt="Chemical Structure 7" /></td>
</tr>
<tr>
<td>8.</td>
<td><img src="image" alt="Chemical Structure 8" /></td>
</tr>
<tr>
<td>9.</td>
<td><img src="image" alt="Chemical Structure 9" /></td>
</tr>
<tr>
<td>10.</td>
<td><img src="image" alt="Chemical Structure 10" /></td>
</tr>
<tr>
<td>11.</td>
<td><img src="image" alt="Chemical Structure 11" /></td>
</tr>
<tr>
<td>12.</td>
<td><img src="image" alt="Chemical Structure 12" /></td>
</tr>
<tr>
<td>13.</td>
<td><img src="image" alt="Chemical Structure 13" /></td>
</tr>
<tr>
<td>14.</td>
<td><img src="image" alt="Chemical Structure 14" /></td>
</tr>
</tbody>
</table>
The compounds as disclosed in the present invention are formulated for pharmaceutical administration.

In one embodiment, the present invention provides a pharmaceutical composition comprising the compound as disclosed, and a pharmaceutically acceptable carrier or a diluent.

In another embodiment, the said pharmaceutical composition further comprising at least one of an anticancer agent, chemotherapy agent, or antiproliferative compound.
In one embodiment, the present invention provides the compounds as disclosed in the present invention for use as a medicament.

In another embodiment, the present invention provides the compounds as disclosed in the present invention for use as a medicament for the treatment of cancer or infectious disease.

In another embodiment, the present invention provides the compounds as disclosed in the present invention for use as a medicament for the treatment of bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.

In another embodiment, the present invention provides the compounds as disclosed in the present invention for use in the treatment of cancer.

In another embodiment, the present invention provides the compounds as disclosed in the present invention for use in the treatment of infectious disease.

In one embodiment, the present invention provides the compounds as disclosed in the present invention for use as a medicament for the treatment of bacterial infectious disease, a viral infectious disease or a fungal infectious disease.

In one embodiment, the present invention provides a method of treatment of cancer, wherein the method comprises administration of an effective amount of the compound of the present invention to the subject in need thereof.
In another embodiment the present invention provides a method of modulating an immune response mediated by PD-1 signaling pathway in a subject, comprising administering to the subject therapeutically effective amount of the compound of the present invention such that the immune response in the subject is modulated.

In yet another embodiment the present invention provides a method of inhibiting growth of tumour cells and/or metastasis in a subject, comprising administering to the subject a therapeutically effective amount of compound of the present invention capable of inhibiting the programmed cell death 1 (PD1) signaling pathway.

The said tumour cells include cancer such as but not limited to bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.

In yet another further embodiment the present invention provides a method of treating an infectious disease in a subject comprising administering to the subject a therapeutically effective amount of the compound of the present invention capable of inhibiting the programmed cell death 1 (PD1) signaling pathway such that the subject is treated for the infectious disease.

Still yet another embodiment of the present invention provides a method of treating bacterial, viral and fungal infections in a subject comprising administering to the subject a therapeutically effective amount of the compound of the present invention
capable of inhibiting the programmed cell death 1 (PD1) signalling pathway such that the subject is treated for the bacterial, viral and fungal infections.

The infectious disease includes but not limited to HIV, Influenza, Herpes, Giardia, Malaria, Leishmania, the pathogenic infection by the virus Hepatitis (A, B, & C), herpes virus (e.g., VZV, HSV-I, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, flaviviruses, echovirus, rhinovirus, coxsackie virus, cornovirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papillomavirus, molluscum virus, poliovirus, rabies virus, JC virus and arboviral encephalitis virus, pathogenic infection by the bacteria chlamidia, rickettsial bacteria, mycobacteria, staphylococci, streptococci, pneumonococci, meningococci and conococci, klebsiella, proteus, serratia, pseudomonas, E. coli, legionella, diphtheria, salmonella, bacilli, cholera, tetanus, botulism, anthrax, plague, leptospirosis, and Lyme's disease bacteria, pathogenic infection by the fungi Candida (albicans, krusei, glabrata, tropicalis, etc.), Cryptococcus neoformans, Aspergillus (fumigatus, niger, etc.), Genus Mucorales (mucor, absidia, rhizopus), Sporothrix schenckii, Blastomyces dermatitidis, Paracoccidioides brasiliensis, Coccidioides immitis and Histoplasma capsulatum, and pathogenic infection by the parasites Entamoeba histolytica, Balantidium coli, Naegleriafowleri, Acanthamoeba sp., Giardia lambia, Cryptosporidium sp., Pneumocystis carinii, Plasmodium vivax, Babesia microti, Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondi, Nippostrongylus brasiliensis.

The compounds of the present invention may be used as single drugs or as a pharmaceutical composition in which the compound is mixed with various pharmacologically acceptable materials.

The pharmaceutical composition is usually administered by oral or inhalation routes, but can be administered by parenteral administration route. In the practice of this invention, compositions can be administered, for example, by orally, intravenous infusion, topically, intraperitoneally, intravesically or intrathecally. Examples of the parenteral administration includes but not limited to intraarticular (in the joints), intravenous, intramuscular, intradermal, intraperitoneal, and subcutaneous routes, include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain antioxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that
can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Oral administration, parenteral administration, subcutaneous administration and intravenous administration are the preferred methods of administration.

The dosage of the compounds of the present invention varies depending on age, weight, symptom, therapeutic efficacy, dosing regimen and/or treatment time. Generally, they may be administered by oral or inhalation routes, in an amount of 1 mg to 100 mg per time, from once a couple of days, once 3 days, once 2 days, once a day to a couple of times a day, in the case of an adult, or continuously administered by oral or inhalation routes from 1 to 24 hours a day. Since the dosage is affected by various conditions, an amount less than the above dosage may sometimes work well enough, or higher dosage may be required in some cases.

The compounds of the present invention may be administered in combination with other drugs for (1) complementation and/or enhancement of prevention and/or therapeutic efficacy of the preventive and/or therapeutic drug of the present invention, (2) dynamics, absorption improvement, dosage reduction of the preventive and/or therapeutic drug of the present invention, and/or (3) reduction of the side effects of the preventive and/or therapeutic drug of the present invention.

A concomitant medicine comprising the compounds of the present invention and other drug may be administered as a combination preparation in which both components are contained in a single formulation, or administered as separate formulations. The administration by separate formulations includes simultaneous administration and administration with some time intervals. In the case of the administration with some time intervals, the compound of the present invention can be administered first, followed by another drug or another drug can be administered first, followed by the compound of the present invention. The administration method of the respective drugs may be the same or different.

The dosage of the other drug can be properly selected, based on a dosage that has been clinically used. The compounding ratio of the compound of the present invention and the other drug can be properly selected according to age and weight of a subject to be administered, administration method, administration time, disorder to be treated, symptom and combination thereof. For example, the other drug may be used in an amount of 0.01 to 100 parts by mass, based on 1 part by mass of the compound of the
present invention. The other drug may be a combination of two or more kind of arbitrary drugs in a proper proportion. The other drug that complements and/or enhances the preventive and/or therapeutic efficacy of the compound of the present invention includes not only those that have already been discovered, but those that will be discovered in future, based on the above mechanism.

Diseases on which this concomitant use exerts a preventive and/or therapeutic effect are not particularly limited. The concomitant medicine can be used for any diseases, as long as it complements and/or enhances the preventive and/or therapeutic efficacy of the compound of the present invention.

The compound(s) of the present invention can be used with an existing chemotherapeutic concomitantly or in a mixture form. Examples of the chemotherapeutic include an alkylation agent, nitrosourea agent, antimetabolite, anticancer antibiotics, vegetable-origin alkaloid, topoisomerase inhibitor, hormone drug, hormone antagonist, aromatase inhibitor, P-glycoprotein inhibitor, platinum complex derivative, other immunotherapeutic drugs and other anticancer drugs. Further, it can be used with a cancer treatment adjunct, such as a leucopenia (neutropenia) treatment drug, thrombocytopenia treatment drug, antiemetic and cancer pain intervention drug, concomitantly or in a mixture form.

In one embodiment, the compound(s) of the present invention can be used with other immunomodulators and/or a potentiating agent concomitantly or in a mixture form. Examples of the immunomodulator include various cytokines, vaccines and adjuvants. Examples of these cytokines, vaccines and adjuvants that stimulates immune responses include but not limited to GM-CSF, M-CSF, G-CSF, interferon-a, β, or γ, IL-1, IL-2, IL-3, IL-12, Poly (I:C) and CpG. In another embodiment, the potentiating agents includes cyclophosphamide and analogs of cyclophosphamide, anti-TGFp and Imatinib (Gleevec), a mitosis inhibitor, such as paclitaxel, Sunitinib (Sutent) or other antiangiogenic agents, an aromatase inhibitor, such as letrozole, an A2a adenosine receptor (A2AR) antagonist, an angiogenesis inhibitor, anthracyclines, oxaliplatin, doxorubicin, TLR4 antagonists, and IL-18 antagonists.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject
matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention.

As used herein, the term 'compound(s)' refers to the compounds disclosed in the present invention.

As used herein, the term "comprise" or "comprising" is generally used in the sense of include, that is to say permitting the presence of one or more features or components.

As used herein, the term "including" as well as other forms, such as "include", "includes," and "included," is not limiting.

As used herein, the term "amino" refers to -N\text{H\textsubscript{4}} group. Unless set forth or recited to the contrary, all amino groups described or claimed herein may be substituted or unsubstituted.

As used herein, the term "amino acid" refers to amino acids having L or D stereochemistry at the alpha carbon.

"Pharmaceutically acceptable salt" is taken to mean an active ingredient, which comprises a compound of the formula (I) in the form of one of its salts, in particular if this salt form imparts improved pharmacokinetic properties on the active ingredient compared with the free form of the active ingredient or any other salt form of the active ingredient used earlier. The pharmaceutically acceptable salt form of the active ingredient can also provide this active ingredient for the first time with a desired pharmacokinetic property which it did not have earlier and can even have a positive influence on the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body.

"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.

The term "stereoisomer" refers to any enantiomers, diastereoisomers, or geometrical isomers of the compounds of formula (I), wherever they are chiral or when they bear one or more double bond. When the compounds of the formula (I) and related formulae are chiral, they can exist in racemic or in optically active form. Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ, it may be desirable to use the enantiomers. In these cases, the
end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or even employed as such in the synthesis. In the case of racemic amines, diastereomers are formed from the mixture by reaction with an optically active resolving agent. Examples of suitable resolving agents are optically active acids such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitable N-protected amino acids (for example N-benzyolproline or N-benzenesulfonylproline), or the various optically active camphorsulfonic acids. Also advantageous is chromatographic enantiomer resolution with the aid of an optically active resolving agent (for example dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatised methacrylate polymers immobilised on silica gel).

The term "subject" includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).

"Therapeutically effective amount" or "efficient amount" refers to sufficient amount of the compound(s) of the present invention that (i) treats or prevents the particular disease, disorder or syndrome (ii) attenuates, ameliorates or eliminates one or more symptoms of the particular disease, disorder or syndrome or (iii) prevents or delays the onset of one or more symptoms of the particular disease, disorder or syndrome described herein. In the case of cancer, the therapeutically effective amount of the drug may decrease the number of cancer cells; decrease the cancer size; inhibit (i.e., slow to some extent and alternatively stop) cancer cell infiltration into peripheral organs; suppress (i.e., slow to some extent and alternatively stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. In the case of infectious disease states, the therapeutic effective amount is an amount sufficient to decrease or alleviate an infectious diseases, the symptoms of an infections caused by bacterial, viral and fungal.

Naturally-occurring amino acids are identified throughout by the conventional three-letter abbreviations indicated in the below table 2.

Table 2 (Amino acid codes)

<table>
<thead>
<tr>
<th>Name</th>
<th>3-letter code</th>
<th>Name</th>
<th>3-letter code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asparagine</td>
<td>Asn</td>
<td>Glutamine</td>
<td>Gin</td>
</tr>
</tbody>
</table>
### Aspartic acid
<table>
<thead>
<tr>
<th>Alanine</th>
<th>Asp</th>
<th>Phenylalanine</th>
<th>Phe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutamic acid</td>
<td>Glu</td>
<td></td>
<td>Thr</td>
</tr>
</tbody>
</table>

The abbreviations used in the entire specification may be summarized hereinbelow with their particular meaning.

°C (degree Celsius); δ (delta); % (percentage); brine (NaCl solution); CH₂Cl₂/DCM (Dichloromethane); br s (Broad singlet); Cs₂CO₃ (Caesium carbonate); d (Doublet); DMF (Dimethyl formamide); DMSO (Dimethyl sulphoxide); DMSO-d₆ (Deuterated DMSO); EDC.HCl/EDCI (1-(3-Dimethyl aminopropyl)-3-carbodiimide hydrochloride); Et₂NH (Diethylamine); Fmoc (Fluorenylmethyloxycarbonyl chloride); g or gr (gram); H or H₂ (Hydrogen); H₂O (Water); HOBT/HOBT (1-Hydroxy benzotriazole); HCl (Hydrochloric acid); h or hr (Hours); Hz (Hertz); HPLC (High-performance liquid chromatography); I₂ (Iodine); K₂CO₃ (Potassium carbonate); LCMS (Liquid chromatography mass spectroscopy); MeOH (Methanol); mmol (Millimoles); M (Molar); μl (Microlitre); mL (Millilitre); mg (Milligram); m (Multiplet); MHz (Megahertz); MS (ES) (Mass spectroscopy-electro spray); min. (Minutes); Na (Sodium); NaHCO₃ (Sodium bicarbonate); NH₂NH₂.H₂O (Hydrazine hydrate); NMM (N-methyl morpholine); Na₂SO₄ (Sodium sulphate); N₂ (Nitrogen); NMR (Nuclear magnetic resonance spectroscopy); PD-L1 (Programmed death-ligand 1); PD-L2 (Programmed cell death 1 ligand 2); prep-HPLC/preparative HPLC (Preparative High-performance liquid chromatography); S (Singlet); Bu (tertiary butyl); TEA/Et₃N (Triethyl amine); TLC (Thin Layer Chromatography); THF (Tetrahydrofuran); TIPS (Triisopropylsilane); TFA/CF₃COOH (Trifluoroacetic acid); t (Triplet); tR = (Retention time); TPP (Triphenylphosphine); etc.

**EXPERIMENTAL**

An embodiment of the present invention provides the preparation of compounds of formula (I) according to the procedures of the following examples, using appropriate materials. Those skilled in the art will understand that known variations of the conditions and processes of the following preparative procedures can be used to prepare these compounds. Moreover, by utilizing the procedures described in detail, one of ordinary skill in the art can prepare additional compounds of the present invention.
The starting materials are generally available from commercial sources such as Sigma-Aldrich, USA or Germany; Chem-Impex USA; G.L. Biochem, China and Spectrochem, India.

**Purification and characterization of compounds**

**Analytical HPLC method:** Analytical HPLC was performed using on ZIC HILIC 200 A0 column (4.6 mm x 250 mm, 5 μM). Flow rate: 1.0 mL / min. The elution conditions used are: Buffer A: 5 mmol ammonium acetate, Buffer B: Acetonitrile, Equilibration of the column with 90 % buffer B and elution by a gradient of 90 % to 40 % buffer B during 30 min.

**Preparative HPLC Method:** Preparative HPLC was performed using on SeQuant ZIC HILIC 200 A0 column (10 mm x 250 mm, 5 μM), Flow rate: 5.0 mL / min. The elution conditions used are: Buffer A: 5 mmol ammonium acetate (adjust to pH-4 with Acetic Acid), Buffer B: Acetonitrile, Equilibration of the column with 90 % buffer B and elution by a gradient of 90 % to 40 % buffer B during 20 min.

LCMS was performed on API 2000 LC/MS/MS triple quad (Applied bio systems) with Agilent 1100 series HPLC with G1315 B DAD, using Mercury MS column or using Agilent LC/MSD VL single quad with Agilent 1100 series HPLC with G1315 B DAD, using Mercury MS column or using Shimadzu LCMS 2020 single quad with Prominence UFLC system with SPD-20 A DAD.

**Example 1: Synthesis of compound 1**

**Step la:**

Potassium carbonate (7.9 g, 57.39 mmol) and Methyl iodide (1.3 mL, 21.04 mmol) were added to a solution of compound 1a (5.0 g, 19.13 mmol) in DMF (35 mL) and stirred at room temperature for 2 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was partitioned between water and ethyl acetate. Organic layer was washed with water, brine, dried over Na2SO4 and evaporated under reduced pressure to get 5.0 g of compound 1b (Yield: 96.1%). LCMS: 176.1 (M-Boc)+.

**Step lb:**
Hydrazine hydrate (7.2 mL) was added to a solution of compound 1b (5.0 g, 18.16 mmol) in methanol (30 mL) and stirred at room temperature for 2 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced pressure, the residue obtained was partitioned between water and ethyl acetate. Organic layer was washed with water, brine, dried over Na2SO4 and evaporated under reduced pressure to get 4.0 g of compound 1c (Yield: 80.0%). LCMS: 276.3 (M+H)+.

**Step 1c:**

NMM (0.67 ml, 6.52 mmol) was slowly added to a stirred solution of 1c (1.2 g, 4.35 mmol), 1d (1.43 g, 4.35 mmol), HOBt (0.7 g, 5.22 mmol) and EDC.HCl (0.99 g, 5.22 mmol) in DMF (15 mL) at 0°C. The reaction mixture was stirred at room temperature for 12 h. The completeness of the reaction was confirmed by TLC analysis. The reaction was quenched with ice and the solid precipitated was filtered and dried under vacuum to obtain 2.0 g of pure product 1e (Yield: 83.3%). LCMS: 591.5 (M+Na)+.

**Step 1d:**

To a stirred solution of 1e (1.5 g, 2.63 mmol) in dry THF (15.0 mL) and DMF (5.0 mL) triphenylphosphine (1.38 g, 5.27 mmol) and iodine (1.33 g, 5.27 mmol) were added at 0°C. After the iodine was completely dissolved, Et3N (1.52 mL, 10.54 mmol) was added to this reaction mixture at ice cold temperature. Reaction mixture was allowed to attain room temperature and stirred for 4 h. The completeness of the reaction was confirmed by TLC analysis. The reaction was quenched with ice water and extracted with ethyl acetate. Organic layer was washed with saturated sodium thiosulphate and brine solution.
The separated Organic layer was dried over Na₂SO₄ and evaporated under reduced pressure to get residue, which was further purified by silica gel column chromatography (eluent: 30% ethyl acetate in hexane) to afford 0.8 g of compound If (Yield: 55%). LCMS: 551.3 (M+H)⁺.

**Step le:**

\[
\text{If} \xrightarrow{\text{Et₂NH/DCM}} \text{Ig}
\]

Fmoc group was deprotected by the addition of diethylamine (20.0 mL) to a solution of compound If (0.8 g, 1.45 mmol) in CH₂Cl₂ (20.0 mL) at 0°C. The reaction was stirred at room temperature for 2 h. The resulting solution was concentrated in vacuum to get a thick gummy residue. The crude compound was purified by neutral alumina column chromatography (eluent: 2% methanol in chloroform) to afford 0.38 g of compound Ig (Yield: 80.0%): LCMS: 329.4 (M+H)⁺.

**Step If:**

\[
\text{Ig} \xrightarrow{\text{Et₃N/DMF}} \text{Ii}
\]

Compound Ig (0.38 g, 1.16 mmol), TEA (0.33 mL, 2.32 mmol) dissolved in DMF (10 mL) were added drop wise to a solution of Ih (0.55 g, 1.39 mmol) at 0°C for urea bond formation and the mixture was stirred at room temperature for 2 h. The completeness of the reaction was confirmed by TLC analysis. The reaction was quenched with ice water, the solid precipitated was filtered and dried under vacuum to get crude compound, which was further purified by silica gel column chromatography (eluent: 0-35% ethyl acetate in hexane) to get 0.4 g of product Ii (Yield: 59.7%). LCMS: 586.4 (M+H)⁺.

**Step Ig:**

\[
\text{Ii} \xrightarrow{\text{CF₃COOH/CH₂Cl₂}} \text{I}
\]
To a solution of compound 1i (0.4 g, 0.68 mmol) in CH₂CI₂ (5 mL), trifluoroacetic acid (5 mL) and catalytic amount of triisopropylsilane were added and stirred at room temperature for 3 h to remove the acid sensitive protecting groups. The resulting solution was concentrated under nitrogen and the solid material was purified by preparative HPLC method as described under experimental conditions (Yield: 0.05 g). LCMS: 318.0 (M+H); HPLC: t_R = 10.96 min.

**Synthesis of compound 1h** (N0₂-C₆H₄-OCO-Thr(tBu)-OtBu):

To a solution of 4-nitrophenylchloroformate (4.79 g, 23.77 mmol) in DCM (25.0 mL) was added a solution of H-Thr(tBu)-OtBu (5.0 g, 21.61 mmol) TEA (6.2 mL, 43.22 mmol) in CH₂CI₂ (25 mL) slowly at 0°C and allowed to stir for 30 min. The completion of the reaction was confirmed by TLC analysis. After completion of reaction it was diluted with DCM and washed with 1.0 M of citric acid followed by 1.0 M sodium carbonate solution. The organic layer was dried over Na₂SO₄ and evaporated under reduced pressure to afford crude compound 1h, which was further purified by silica gel column chromatography (eluent: 0-5% ethyl acetate in hexane) to get 3.0 g of product 1h. ¹H NMR (CDCl₃, 400 MHz): δ 1.17 (s, 9H), 1.28 (d, 3H), 1.50 (s, 9H), 4.11 (m, 1H), 4.28 (m, 1H), 5.89 (d, 1H), 7.37 (d, 2H), 8.26 (d, 2H).

**Example 2: Synthesis of compound 2**

**Step 2a:**

NMM (1.8 mL, 18.15 mmol) was slowly added to a stirred solution of 1c (2.0 g, 7.26 mmol), 2d (4.3 g, 7.26 mmol), HOBt (1.17 g, 8.7 mmol) and EDC.HCl (1.66 g, 8.7 mmol) in DMF (15 mL) at 0°C. The reaction mixture was stirred at room temperature for 12 h. The completeness of the reaction was confirmed by TLC analysis. The reaction
was quenched with ice, the solid precipitated was filtered and dried under vacuum to afford 3.7 g of pure product 2e (Yield: 59.6%). LCMS: 854.4 (M+H)+.

**Step 2b:**

To a stirred solution of 2e (3.7 g, 4.33 mmol) dissolved in dry THF (25.0 mL) and DMF (10.0 mL), triphenylphosphine (2.28 g, 8.66 mmol) and iodine (2.2 g, 8.66 mmol) were added at 0°C. After the iodine was completely dissolved, Et₃N (2.5 mL, 17.32 mmol) was added at same temperature. The reaction mixture was stirred at room temperature for 4 h. The completeness of the reaction was confirmed by TLC analysis. The reaction was quenched with ice water and extracted with ethyl acetate. The organic layer was washed with saturated sodium thiosulphate and brine solution. The separated organic layer was dried over Na₂SO₄ and evaporated under reduced pressure, which was further purified by silica gel column chromatography (eluent: 30% ethyl acetate in hexane) to get 2.0 g of compound 2f (Yield: 55%). LCMS: 858.4 (M+Na)+.

**Step 2c:**

Diethylamine (30.0 mL) was added to a solution of compound 2f (2.0 g, 1.17 mmol) in CH₂Cl₂ (30.0 mL) at 0°C. The reaction mixture was stirred at room temperature for 1 h. The resulting solution was concentrated in vacuum to get a thick gummy residue. The crude compound was purified by neutral alumina column chromatography (eluent: 2% methanol in chloroform) to afford 1.0 g of compound 2g (Yield: 71.4%). LCMS: 614.5 (M+H)+.

**Step 2d:**
compound 2g (1.0 g, 1.63 mmol) and TEA (0.47 mL, 3.2 mmol) dissolved in DMF (10 mL) were added drop wise to a solution of 1h (0.7 g, 1.79 mmol) at 0 °C. The reaction mixture was then allowed to reach room temperature and continued the stirring for 2 h. The completeness of the reaction was confirmed by TLC analysis. The reaction was quenched with ice water, the solid precipitated was filtered and dried under vacuum. The crude compound obtained was further purified by silica gel column chromatography (eluent: 0-30% ethyl acetate in hexane) to get 0.8 g of product 2i (Yield: 57.1%). LCMS: 871.6 (M+H)+.

Step 2e:

To a solution of compound 2i (0.8 g, 0.92 mmol) in CH₂Cl₂ (6 mL), trifluoroacetic acid (6 mL) and catalytic amount of triisopropylsilane were added and stirred at room temperature for 3 h. The resulting solution was concentrated under nitrogen and the solid material was purified by preparative HPLC method described under experimental conditions (Yield: 0.065 g). HPLC: tᵣ = 12.01 min.; LCMS: 361.34 (M+H)+.

Example 3: Synthesis of compound 3

Step 3a:

Lawesson's reagent (2.85 g, 7.03 mmol) was added to a solution of compound 2e (4 g, 4.68 mmol) in THF (40 mL) and stirred at 75°C for 4 h. The completeness of the reaction was confirmed by TLC analysis. The reaction mixture was evaporated under reduced
pressure and the obtained residue was partitioned between ice water and ethyl acetate. The organic layer was washed with NaHCO₃ solution followed by brine solution. The organic layer was dried over Na₂SO₄, filtered and evaporated under reduced pressure to get residue which was further purified by silica gel column chromatography (eluent: 0-5% ethyl acetate in hexane) to afford 2.7 g of compound 3a (Yield: 67.66%). LCMS: 852.3 (M+H)⁺.

**Step 3b:**

\[ \text{Fmoc group on compound 3a was deprotected by adding diethylamine (3.8 mL) to the solution of compound 3a (1 g, 1.17 mmol) in CH}_2\text{Cl}_2 (3.8 mL). The reaction mixture was stirred at room temperature for 30 min. The resulting solution was concentrated in vacuum to get a thick gummy residue. The crude compound was purified by neutral alumina column chromatography (eluent: 0-50% ethyl acetate in hexane then 0-5% methanol in chloroform) to attain 0.62 g of compound 3b. LCMS: 630.5 (M+H)⁺.} \]

**Step 3c:**

\[ \text{To a solution of compound 3b (0.6 g) in CH}_2\text{Cl}_2 (7.5 mL), trifluoroacetic acid (2.5 mL) and catalytic amount of trisopropylsilane were added and stirred at room temperature for 3 h. The resulting solution was concentrated in vacuum to get 0.13 g of compound 3. which was purified by preparative HPLC method described under experimental conditions. LCMS: 232.3 (M+H)⁺.} \]

**Example 4: Synthesis of compound 4**

**Step 4a:**

The urea linkage was carried out by coupling of compound 3b (0.5 g, 7.9 mmol) in THF (10 mL) at room temperature with compound 4e (0.34 g, 7.9 mmol). The coupling was initiated by the addition of TEA (0.16 g, 15.8 mmol) in THF (10 mL) and the resultant mixture was stirred at room temperature. After 12 h, THF was evaporated from the reaction mass, and partitioned between water and ethyl acetate. The organic layer was washed with water, brine, dried over Na₂SO₄ and evaporated under reduced pressure to yield 4a, which was further purified by silica gel column chromatography (eluent: 0-50% ethyl acetate in hexane) to get 0.45 g of product 4a (Yield: 61.64%). LCMS: 921.8 (M+H)⁺.

**Step 4b:**

To a solution of compound 4a (0.55 g) in methanol (20 mL), was added 10% Pd-C (0.15 g) under inert atmosphere. The mixture was stirred for 1 h under H₂ atmosphere. The completion of the reaction was confirmed by TLC analysis. The Pd-C catalyst was then removed by filtration through a Celite® pad and washed with 20 mL of methanol. The combined organic filtrate on evaporation under reduced pressure resulted in the isolation of the product 4b (Yield: 0.42 g, 85.71%). LCMS: 831.5 (M+H)⁺.

**Step 4c:**

To a solution of compound 4b (0.2 g, 0.3 mmol) in CH₂Cl₂ (5 mL), trifluoroacetic acid (5 mL) and catalytic amount of triisopropylsilane were added and stirred at room
temperature for 3h. The resulting solution was concentrated in vacuum and the solid material was purified by preparative HPLC method described under experimental conditions (Yield: 0.065 g). HPLC: $t_R = 14.1 \text{ min}$; LCMS: 377.3 (M+H)+.

**Synthesis of compound 4e, (NO$_2$-C$_6$H$_4$-OCO-Thr(O'Bu)-Bzl):**

To a solution of compound Fmoc-Thr('Bu)-OH (15 g, 37.73 mmol) in 100 mL of DMF, Cs$_2$CO$_3$ (14.75 g, 45.2 mmol) was added and the resulting mixture was cooled to 0 °C. To the cooled reaction mixture benzyl bromide (7.74 g, 45.2 mmol) was added and the solution was stirred at ice cold temperature for 30 min and then at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure and diluted with ethyl acetate. The organic layer was washed with water followed by brine solution and dried over Na$_2$SO$_4$. The filtered solution was concentrated and purified by silica gel column chromatography (eluent: 0-30% ethyl acetate in hexane) to get 18 g of 4c as white solid. LCMS: 433.1 (M-OBz), 397.2 (M-OBzl)+.

Fmoc group on compound 4c (25 g, 51.3 mmol) was deprotected by adding diethylamine (100 mL) to compound 4d (25 g, 51.3 mmol) in CH$_2$Cl$_2$ (100 mL) for 1 h with stirring at room temperature. The resulting solution was concentrated in vacuum and the thick residue was purified by neutral alumina column chromatography (eluent: 0-50% ethyl acetate in hexane then 0-5% methanol in chloroform) to afford 10.6 g of compound 4d.

**LCMS: 266.5 (M+H)+.**

To a solution of compound 4d (1.5 g, 5.65 mmol) in CH$_2$Cl$_2$ (25 mL) was added TEA (1.14 g, 11.3 mmol) and the solution was stirred at room temperature for 5-10 min. To this mixture a solution of 4-nitrophenyl chloroformate (1.4 g, 6.78 mmol) in CH$_2$Cl$_2$ (10 mL) was added and the resultant mixture was stirred at room temperature for 12 h. The completion of the reaction was confirmed by TLC analysis. After completion of reaction it was diluted with DCM and washed with 1.0 M of sodium bisulphate solution followed
by 1.0 M sodium carbonate solution. The organic layer was dried over Na₂SO₄, filtered and evaporated under reduced pressure to yield crude compound 4e, which was further purified by silica gel column chromatography (eluent: 0-20% ethyl acetate in hexane) to yield 0.7 g of product 4e. ¹H NMR (DMSO-d₆, 300 MHz): δ1.04 (s, 9H), 1.16 (d, 3H), 4.11 (m, 1H), 5.11 (m, 3H), 6.91 (d, 2H), 7.40 (m, 5H), 8.10 (d, 2H), 8.26 (br s, 1H).

The compounds in table 3 below were prepared based on the experimental procedures described above.

<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Structure</th>
<th>LCMS (M+H)⁺</th>
<th>HPLC tᵣ in min</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.</td>
<td><img src="image" alt="Structure 5" /></td>
<td>391.1</td>
<td>12.43</td>
</tr>
<tr>
<td>6.</td>
<td><img src="image" alt="Structure 6" /></td>
<td>377.1</td>
<td></td>
</tr>
<tr>
<td>7.</td>
<td><img src="image" alt="Structure 7" /></td>
<td>361.1</td>
<td>12.21</td>
</tr>
<tr>
<td>8.</td>
<td><img src="image" alt="Structure 8" /></td>
<td>230.1</td>
<td>12.95</td>
</tr>
<tr>
<td>9.</td>
<td><img src="image" alt="Structure 9" /></td>
<td>375.4</td>
<td>11.55</td>
</tr>
<tr>
<td>10.</td>
<td><img src="image" alt="Structure 10" /></td>
<td>361.2</td>
<td>11.91</td>
</tr>
<tr>
<td></td>
<td>Chemical Structure</td>
<td>Molecular Weight</td>
<td>pKa</td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
<td>------------------</td>
<td>------</td>
</tr>
<tr>
<td>11.</td>
<td><img src="image" alt="Chemical Structure 11" /></td>
<td>361.1</td>
<td>12.08</td>
</tr>
<tr>
<td>12.</td>
<td><img src="image" alt="Chemical Structure 12" /></td>
<td>375.2</td>
<td>11.5</td>
</tr>
<tr>
<td>13.</td>
<td><img src="image" alt="Chemical Structure 13" /></td>
<td>389.1</td>
<td>11.10</td>
</tr>
<tr>
<td>14.</td>
<td><img src="image" alt="Chemical Structure 14" /></td>
<td>347.1</td>
<td>12.58</td>
</tr>
<tr>
<td>15.</td>
<td><img src="image" alt="Chemical Structure 15" /></td>
<td>376.1</td>
<td>12.20</td>
</tr>
<tr>
<td>16.</td>
<td><img src="image" alt="Chemical Structure 16" /></td>
<td>375.2</td>
<td>11.91</td>
</tr>
<tr>
<td>17.</td>
<td><img src="image" alt="Chemical Structure 17" /></td>
<td>361.2</td>
<td>12.34</td>
</tr>
<tr>
<td>18.</td>
<td><img src="image" alt="Chemical Structure 18" /></td>
<td>362.1</td>
<td>12.50</td>
</tr>
</tbody>
</table>
The compounds shown in below table 4, which can be prepared by following similar procedure as described above with suitable modification known to the one ordinary skilled in the art are also included in the scope of the present application.

Table 4

<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Structure</th>
<th>Compound No.</th>
<th>Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.</td>
<td><img src="image1.png" alt="Structure 19" /></td>
<td>348.1</td>
<td><img src="image2.png" alt="Structure 348.1" /></td>
</tr>
<tr>
<td>20.</td>
<td><img src="image3.png" alt="Structure 20" /></td>
<td>391.1</td>
<td><img src="image4.png" alt="Structure 391.1" /></td>
</tr>
</tbody>
</table>

| 21.          | ![Structure 21](image5.png) | 26.          | ![Structure 26](image6.png) |
| 22.          | ![Structure 22](image7.png) | 27.          | ![Structure 27](image8.png) |
| 23.          | ![Structure 23](image9.png) | 28.          | ![Structure 28](image10.png) |
| 24.          | ![Structure 24](image11.png) | 29.          | ![Structure 29](image12.png) |
| 25.          | ![Structure 25](image13.png) |             | -          |
Rescue of mouse splenocyte proliferation in the presence of recombinant PD-L1/PD-L2:

Recombinant mouse PD-L1 (rm-PDL-1, cat no: 1019-B7-100 and R&D Systems) were used as the source of PD-L1.

Requirement:
Mouse splenocytes harvested from 6-8 weeks old C57 BL6 mice; RPMI 1640 (GIBCO, Cat # 11875); DMEM with high glucose (GIBCO, Cat # D6429); Fetal Bovine Serum [Hyclone, Cat # SH30071.03]; Penicillin (10000unit/ml)-Streptomycin(10,000 µg/ml) Liquid (GIBCO, Cat # 15140-122); MEM Sodium Pyruvate solution 100mM lOOx; (GIBCO, Cat # 11360); Nonessential amino acid (GIBCO, Cat # 11140); L-Glutamine (GIBCO, Cat # 25030); Anti-CD3 antibody (eBiosciences - 16-0032); Anti-CD28 antibody (eBiosciences - 16-0281); ACK lysis buffer (lmL) (GIBCO, Cat # - A10492); Histopaque (density-1.083 gm/mL) (SIGMA 10831); Trypan blue solution (SIGMA-T8154); 2 mL Norm Ject Luer Lock syringe- (Sigma 2014-12); 40 µM stock solution of CFSE: CFSE stock solution was prepared by diluting lyophilized CFSE with 180 µL of Dimethyl sulfoxide (DMSO C₂H₆SO, SIGMA-D-5879) and aliquoted in to tubes for further use. Working concentrations were titrated from 10 µM to 1 µM. (eBioscience-650850-85); 0.05% Trypsin and 0.02% EDTA (SIGMA 59417C); 96-well format ELISA plates (Corning CLS3390); BD FACS caliber (E6016); Recombinant mouse B7-H1/PDL1 Fc Chimera, (rm-PDL1 cat no: 1019-B7-100).

Protocol

Splenocyte preparation and culturing:
Splenocytes harvested in a 50 mL falcon tube by mashing mouse spleen in a 40 µm cell strainer were further treated with 1 mL ACK lysis buffer for 5 min at room temperature. After washing with 9 mL of RPMI complete media, cells were re-suspended in 3 mL of lxPBS in a 15 mL tube. 3 mL of Histopaque was added carefully to the bottom of the tube without disturbing overlaying splenocyte suspension. After centrifuging at 800xg for 20 min at room temperature, the opaque layer of splenocytes was collected carefully
without disturbing / mixing the layers. Splenocytes were washed twice with cold 1xPBS followed by total cell counting using Trypan Blue exclusion method and used further for cell based assays.

Splenocytes were cultured in RPMI complete media (RPMI + 10% fetal bovine serum + 1 mM sodium pyruvate + 10,000 units/ml penicillin and 10,00C^g/ml streptomycin) and maintained in a C% incubator with 5% C% at 37°C.

**CFSE Proliferation assay:**
CFSE is a dye that passively diffuses into cells and binds to intracellular proteins. 1x10^6 cells/mL of harvested splenocytes were treated with 5 µM of CFSE in pre-warmed 1xPBS/0.1% BSA solution for 10 min at 37°C. Excess CFSE was quenched using 5 volumes of ice-cold culture media to the cells and incubated on ice for 5 min. CFSE labelled splenocytes were further given three washes with ice cold complete RPMI media. CFSE labelled 1x10^5 splenocytes added to wells containing either MDA-MB231 cells (1x10^5 cells cultured in high glucose DMEM medium) or recombinant human PDL-1 (100 ng/mL) and test compounds. Splenocytes were stimulated with anti-mouse CD3 and anti-mouse CD28 antibody (1 µg/mL each), and the culture was further incubated for 72 h at 37°C with 5% CO_2. Cells were harvested and washed thrice with ice cold FACS buffer and % proliferation was analyzed by flow cytometry with 488 nm excitation and 521 nm emission filters.

**Data compilation, processing and inference:**
Percent splenocyte proliferation was analyzed using cell quest FACS program and percent rescue of splenocyte proliferation by compound was estimated after deduction of % background proliferation value and normalising to % stimulated splenocyte proliferation (positive control) as 100%.

**Stimulated splenocytes:** Splenocytes + anti-CD3/CD28 stimulation
**Background proliferation:** Splenocytes + anti-CD3/CD28 + PD-L1
**Compound proliferation:** Splenocytes + anti-CD3/CD28 + PD-L1 + Compound

Compound effect is examined by adding required concentration of compound to anti-CD3/CD28 stimulated splenocytes in presence of ligand (PDL-1)

**Table 5**
<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Percent rescue of splenocyte proliferation (@100 nM compound concentration)</th>
<th>Compound No.</th>
<th>Percent rescue of splenocyte proliferation (@100 nM compound concentration)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>61.2</td>
<td>13</td>
<td>75</td>
</tr>
<tr>
<td>2</td>
<td>80.3</td>
<td>14</td>
<td>53</td>
</tr>
<tr>
<td>3</td>
<td>48.4</td>
<td>15</td>
<td>69</td>
</tr>
<tr>
<td>4</td>
<td>60</td>
<td>16</td>
<td>56</td>
</tr>
<tr>
<td>9</td>
<td>74</td>
<td>17</td>
<td>53</td>
</tr>
<tr>
<td>10</td>
<td>58</td>
<td>18</td>
<td>68</td>
</tr>
<tr>
<td>12</td>
<td>92</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
We claim:

1. A compound of formula (I)

   \[
   \begin{array}{c}
   \text{H}_2\text{N} \\
   \text{R}_1 \quad \text{X} \quad \text{R}_3 \\
   \text{N} \quad \text{R}_2 \\
   \text{R}_4 \quad \text{R}_5 \\
   \end{array}
   \]

   wherein,
   \( R_1 \) is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
   \( X \) is S or O;
   \( R_2 \) is hydrogen or -CO-Aaa;
   Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified;

   \( R_3 \) is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
   — is an optional bond;
   \( R_4 \) and \( R_5 \) independently are hydrogen or absent;
   or a pharmaceutically acceptable salt or a stereoisomer thereof.

2. The compound according to claim 1 is a compound of formula (IA):

   \[
   \begin{array}{c}
   \text{H}_2\text{N} \\
   \text{R}_1 \quad \text{X} \quad \text{R}_3 \\
   \text{N} \quad \text{R}_2 \\
   \end{array}
   \]

   or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,

   \( R_1 \) is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
   \( X \) is S or O;
   \( R_2 \) is hydrogen or -CO-Aaa;

   \( R_3 \) is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
   Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified.

3. The compound according to any one of claims 1 to 2, is a compound of formula (IB):
or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
R₁ is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
R₃ is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified.

4. The compound according to any one of claims 1 to 2, is a compound of formula (IC):

or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein,
R₁ is side chain of an amino acid selected from Ser, Thr, Phe, Ala or Asn;
R₃ is side chain of an amino acid selected from Ser, Ala, Glu, Gin, Asn or Asp;
Aaa is an amino acid residue selected from Ser, Asn or Thr; wherein a C-terminus thereof is a free terminus, is amidated or is esterified.

5. The compound according to any one of claims 1 to 2, wherein X is O.
6. The compound according to any one of claims 1 to 2, wherein X is S.
7. The compound according to claim 1, wherein
R₁ is side chain of Ser or Thr;
R₂ is -CO-Aaa;
Aaa is an amino acid residue Ser or Thr; wherein the C-terminus is free;
R₃ is side chain of Asn, Gin, Glu or Asp.
8. The compound according to any one of claims 1 to 2, wherein R₂ is hydrogen.
9. A compound according to claim 1 is selected from the group consisting of

<table>
<thead>
<tr>
<th>Compound No.</th>
<th>Structure</th>
</tr>
</thead>
</table>

...
<table>
<thead>
<tr>
<th></th>
<th>Chemical Structure</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td><img src="image1" alt="Chemical Structure 1" /></td>
</tr>
<tr>
<td>2.</td>
<td><img src="image2" alt="Chemical Structure 2" /></td>
</tr>
<tr>
<td>3.</td>
<td><img src="image3" alt="Chemical Structure 3" /></td>
</tr>
<tr>
<td>4.</td>
<td><img src="image4" alt="Chemical Structure 4" /></td>
</tr>
<tr>
<td>5.</td>
<td><img src="image5" alt="Chemical Structure 5" /></td>
</tr>
<tr>
<td>6.</td>
<td><img src="image6" alt="Chemical Structure 6" /></td>
</tr>
<tr>
<td>7.</td>
<td><img src="image7" alt="Chemical Structure 7" /></td>
</tr>
<tr>
<td>8.</td>
<td><img src="image8" alt="Chemical Structure 8" /></td>
</tr>
<tr>
<td>9.</td>
<td><img src="image9" alt="Chemical Structure 9" /></td>
</tr>
<tr>
<td></td>
<td>Molecular Structure</td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
</tr>
<tr>
<td>10</td>
<td><img src="image1" alt="Structure 10" /></td>
</tr>
<tr>
<td>11</td>
<td><img src="image2" alt="Structure 11" /></td>
</tr>
<tr>
<td>12</td>
<td><img src="image3" alt="Structure 12" /></td>
</tr>
<tr>
<td>13</td>
<td><img src="image4" alt="Structure 13" /></td>
</tr>
<tr>
<td>14</td>
<td><img src="image5" alt="Structure 14" /></td>
</tr>
<tr>
<td>15</td>
<td><img src="image6" alt="Structure 15" /></td>
</tr>
<tr>
<td>16</td>
<td><img src="image7" alt="Structure 16" /></td>
</tr>
<tr>
<td>17</td>
<td><img src="image8" alt="Structure 17" /></td>
</tr>
<tr>
<td></td>
<td>Chemical Structure</td>
</tr>
<tr>
<td>---</td>
<td>-------------------</td>
</tr>
<tr>
<td>18.</td>
<td><img src="image18.png" alt="Chemical Structure 18" /></td>
</tr>
<tr>
<td>19.</td>
<td><img src="image19.png" alt="Chemical Structure 19" /></td>
</tr>
<tr>
<td>20.</td>
<td><img src="image20.png" alt="Chemical Structure 20" /></td>
</tr>
<tr>
<td>21.</td>
<td><img src="image21.png" alt="Chemical Structure 21" /></td>
</tr>
<tr>
<td>22.</td>
<td><img src="image22.png" alt="Chemical Structure 22" /></td>
</tr>
<tr>
<td>23.</td>
<td><img src="image23.png" alt="Chemical Structure 23" /></td>
</tr>
<tr>
<td>24.</td>
<td><img src="image24.png" alt="Chemical Structure 24" /></td>
</tr>
<tr>
<td>25.</td>
<td><img src="image25.png" alt="Chemical Structure 25" /></td>
</tr>
<tr>
<td>26.</td>
<td><img src="image26.png" alt="Chemical Structure 26" /></td>
</tr>
</tbody>
</table>
10. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 9 or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable carrier or excipient.

11. The pharmaceutical composition according to claim 10, comprising at least one additional pharmaceutical agent wherein the said additional pharmaceutical agent is an anticancer agent, chemotherapy agent, or antiproliferative compound.

12. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt or a stereoisomer thereof, for use as a medicament.

13. A compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt or a stereoisomer thereof, for use as a medicament for the treatment of cancer or infectious disease.

14. A compound for use according to claim 13, wherein the cancer is selected from bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal
pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.

15. A compound for use according to claim 13, wherein the infectious disease is a bacterial infectious disease, a viral infectious disease or a fungal infectious disease.

16. A method of modulating an immune response mediated by PD-1 signaling pathway in a subject, comprising administering to the subject therapeutically effective amount of a compound according to any one of claims 1 to 9.

17. A method of inhibiting growth of tumour cells and/or metastasis in a subject, comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 9.

18. The method of claim 15, wherein the tumour cells are of a cancer selected from the group consisting of breast cancer, colon cancer, lung cancer, melanoma, prostate cancer and renal cancer.

19. The method of claim 15, wherein the tumour cells are of a cancer selected from the list consisting of bone cancer, cancer of the head or neck, pancreatic cancer, skin cancer, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, and combinations of said cancers.
20. A method of treating an infectious disease in a subject comprising administering to the subject a therapeutically effective amount of compound according to any one of claims 1 to 9.

21. A method of treating bacterial, viral and fungal infections in a subject comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 9.
### INTERNATIONAL SEARCH REPORT

**International application No.**

| Form PCT/ISA/210 (second sheet) (July 2009) |

### A. CLASSIFICATION OF SUBJECT MATTER

- C07D 271/06(2006.01)i; C07D 285/08(2006.01)i; A61K 31/4245(2006.01)i; A61K 31/433(2006.01)i; A61P 31/00(2006.01)i; A61P 35/00(2006.01)i

According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

- C07D271/-, C07D285/-, A61P31/-, A61P35/-

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of data base and, where practicable, search terms used)

- CNABS; VEN; CNKI; WPI; EPDOC; REG; CAPLUS; oxadiazole, thiadiazole, programmed cell death, PD. infect*, tumor, cancer, immun*, amino acids, AURIGENE DISCOVERY TECHNOLOGIES, substructure search according to formula (I)

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 2009264315 A1 (TEXAS A &amp; M UNIV SYS) 22 October 2009 (2009-10-22) see the whole document, especially description, paragraphs [0004]-[0006], [0035] and [0039]</td>
<td>1-21</td>
</tr>
<tr>
<td>A</td>
<td>WO 2012168944 A1 (AURIGENE DISCOVERY TECH LTD) 13 December 2012 (2012-12-13) see the whole document</td>
<td>1-21</td>
</tr>
<tr>
<td>A</td>
<td>WO 2011161699 A2 (AURIGENE DISCOVERY TECH LTD) 29 December 2011 (2011-12-29) see the whole document</td>
<td>1-21</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
  
  "A" document defining the general state of the art which is not considered to be of particular relevance
  "E" earlier application or patent but published on or after the international filing date
  "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means
  "O" document published prior to the international filing date but later than the priority date claimed
  "R" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  "&" document member of the same patent family

Date of the actual completion of the international search: 17 December 2014

Date of mailing of the international search report: 26 January 2015

Name and mailing address of the ISA/CN

STATE INTELLECTUAL PROPERTY OFFICE OF THE P.R.CHINA (ISA/CN)

6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing 100088 China

Facsimile No. (86-10)62019451

Authorized officer: XU, Chi

Telephone No. (86-10)62086349
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 16-21
   because they relate to subject matter not required to be searched by this Authority, namely:
   [1] Claims 16-21 relate to a method of treatment of the human or animal body by therapy (see PCT Rule 39.1.(iv)). However, the search has been carried out and based on the use of the compound in manufacture of medicaments for treating corresponding diseases.

2. Claims Nos.:
   because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos.:
   because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date (day/month/year)</th>
<th>Patent family member(s)</th>
<th>Publication date (day/month/year)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>EP 2717895 A1</td>
<td>16 April 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 103732238 A</td>
<td>16 April 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>MX 2012014785 A</td>
<td>29 April 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20140002594 A</td>
<td>08 January 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2011161699 A3</td>
<td>18 May 2012</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AU 2011268484 A1</td>
<td>31 January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SG 186809 A1</td>
<td>28 February 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2803859 A1</td>
<td>29 December 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2013534922 A</td>
<td>09 September 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CN 103096915 A</td>
<td>08 May 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2011318373 A1</td>
<td>29 December 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 2585099 A2</td>
<td>01 May 2013</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (July 2009)